News

AVI BioPharma and Charley’s Fund, a not for profit organization, have amended their existing sponsored research agreement to provide for an additional $3 million in sponsored research funds.

Novavax, and the Division of Microbiology and Infectious Diseases (DMID) have entered into an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against

Lpath has been awarded a $3 million grant by the National Cancer Institute (NCI). The funds will support the continued clinical development of Lpath’s drug candidate, ASONEP, which

Abbott and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott’s Trilipix (fenofibric acid). Its a medication to be used alone or

Acces has declared that new Thiarabine preclinical efficacy data will shortly be published, demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either

Santaris Pharma has announced that the cancer drug EZN-2968, an inhibitor of HIF, is being evaluated in patients with solid tumors and lymphoma. EZN-2968 is well tolerated, and

Asymchem has declared the issuance of a manufacturing certificate for drug products to its Tianjin 2 site, by the Tianjin branch of the Chinese State Food and Drug

Neuralstem has received a patent allowance from the US Patent and Trademark Office (USPTO) for several compounds that can help grow new neurons. Patent application 12/049,922, entitled Use

Novartis has announced that the Novartis Vaccines Institute for Global Health has been awarded a grant from the Wellcome Trust to develop a bivalent vaccine for typhoid fever.